Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...
Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.
The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...
If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...
The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...
This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...
The U.S. Food and Drug Administration (FDA) has approved a new class of antibiotics for treating uncomplicated urinary tract ...
The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be available in the second half of 2025.
The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...
The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be ...
Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes. Study participants were ...
The FDA approved gepotidacin for the treatment of uncomplicated UTIs in women and adolescent girls aged 12 years or older, ...